High-throughout sequencing of triple negative breast cancer cells treated actived compound D16

The high-throughput sequencing technology was performed after the treatment of human triple negative breast cancer cells MDA-MB-231 with the active compound D16 designed and synthesized by ourselves, to explore the expression of genes related to cell proliferation, adhesion, migration and invasion of human triple negative breast cancer cells MDA-MB-231 after the treatment of the active compound Changes to explore the effect of active compounds on the proliferation and motility of triple breast breast cancer cells and to find an interesting target gene, CKAP2. Human triple negative breast cancer cells MDA-MB-231 were treated with active compound D16 at the concentration of 24µM for 48 hours.